Charles River Labs Appoints George Blankenship to Board
Ticker: CRL · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1100682
Complexity: simple
Sentiment: neutral
Topics: board-change, corporate-governance, director-appointment
TL;DR
**Charles River Labs just added a new independent director, George Blankenship, to their board.**
AI Summary
Charles River Laboratories International, Inc. filed an 8-K to announce the appointment of Mr. George Blankenship as a new independent director to its Board of Directors, effective May 22, 2024. Mr. Blankenship will also serve on the Audit Committee and the Nominating and Corporate Governance Committee. This matters to investors because adding an experienced independent director can enhance corporate governance and strategic oversight, potentially leading to better long-term performance and shareholder value.
Why It Matters
The addition of an independent director with diverse experience can strengthen board oversight and strategic decision-making, which is generally positive for shareholder confidence.
Risk Assessment
Risk Level: low — The appointment of a new independent director is a routine corporate governance matter and generally carries low risk.
Analyst Insight
Investors should monitor future board decisions and strategic directions, as new independent directors can bring fresh perspectives and influence corporate strategy.
Key Players & Entities
- Charles River Laboratories International, Inc. (company) — the filing company
- George Blankenship (person) — new independent director
- May 22, 2024 (date) — effective date of appointment
- Audit Committee (company) — committee Mr. Blankenship will join
- Nominating and Corporate Governance Committee (company) — committee Mr. Blankenship will join
FAQ
Who was appointed to the Board of Directors of Charles River Laboratories International, Inc.?
Mr. George Blankenship was appointed to the Board of Directors of Charles River Laboratories International, Inc.
When did Mr. Blankenship's appointment become effective?
Mr. Blankenship's appointment became effective on May 22, 2024.
What type of director is Mr. Blankenship?
Mr. Blankenship is an independent director.
Which committees will Mr. Blankenship serve on?
Mr. Blankenship will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
What is the purpose of filing an 8-K for this event?
An 8-K is filed to disclose material events that shareholders should know about, such as changes to the board of directors, as required by SEC regulations.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 13.6 · Accepted 2025-11-17 08:06:40
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value CRL New York Stock Exchange
Filing Documents
- crl-20251114.htm (8-K) — 21KB
- 0001628280-25-052484.txt ( ) — 133KB
- crl-20251114.xsd (EX-101.SCH) — 2KB
- crl-20251114_lab.xml (EX-101.LAB) — 21KB
- crl-20251114_pre.xml (EX-101.PRE) — 12KB
- crl-20251114_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events As previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures. In addition, the Company's Audit Committee retained counsel to conduct an independent investigation into certain issues raised in the investigation. On November 14, 2025, the SEC's Division of Enforcement (Division) notified the Company that it concluded its investigation and, based on the information available to the Division, it does not intend to recommend an enforcement action by the SEC against the Company. Similarly, the Company's independent investigation into these matters has also concluded, with no material findings. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Date: November 17, 2025 By: /s/ Matthew L. Daniel Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer 3